Results 171 to 180 of about 166,889 (307)

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Eugenia

open access: yes, 2013
Eugeni
Alyson Miller (13058139)
core  

MorFunSeed: A Morphological and Functional Seed Database of Tree and Shrub Species Commonly Used for Direct Seeding in the Cerrado and Atlantic Forest Biomes of Brazil

open access: yesEcological Research, Volume 41, Issue 4, July 2026.
The MorFunSeed dataset compiles standardized seed morphology and functional traits for 131 tree and shrub species native to Brazil's Cerrado and Atlantic Forest biomes. It includes 26 variables and 3406 records, providing a consistent and comparable structure across species.
Mariane Cristina Inocente   +4 more
wiley   +1 more source

Correction: Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results. [PDF]

open access: yesRadiol Med
Vizzuso A   +10 more
europepmc   +1 more source

Risk of SARS‐CoV‐2 Infection and Hospitalisation in Immunocompromised Children: A Population‐Based Cohort Study in Italy and Norway

open access: yesActa Paediatrica, Volume 115, Issue 7, Page 1451-1460, July 2026.
ABSTRACT Aim Immunocompromised children (IC) were presumed to be at higher risk of SARS‐COV‐2 infection and severe COVID‐19, but population‐based evidence is limited. We assessed infection risk, COVID‐19 hospitalisation, and severe outcomes in IC compared with children with and without other high‐risk conditions.
Costanza Di Chiara   +13 more
wiley   +1 more source

Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]. [PDF]

open access: yesJ Prev Alzheimers Dis
Perry R   +13 more
europepmc   +1 more source

Interview with Eugenia Koussidis, formerly Eva Koussidis

open access: yes, 2008
Don Dunstan Oral History Project interview transcripts. No conditions are imposed on the reuse of this transcript by the interviewee.Interview with Eugenia Koussidis, formerly known as Eva Koussidis, by George Lewkowicz.
Koussidis, Eugenia [Interviewee]   +1 more
core  

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6324-6333, July 2026.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney   +14 more
wiley   +1 more source

In Silico and In Vitro Antiurolithic Effect of Extracts, Fractions, and Isolated Compounds From Eugenia mattosii. [PDF]

open access: yesChem Biodivers
Maciél BL   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy